Central pathology laboratory review of HER2 and ER in early breast cancer: An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 485-492

  McCullough, Ann E ^a   Dell'Orto, Patrizia ^b   Reinholz, Monica M ^c   Gelber, Richard D ^d,e   Dueck, Amylou C ^a   Russo, Leila ^b   Jenkins, Robert B ^f   Andrighetto, Stefania ^b   Chen, Beiyun ^f   Jackisch, Christian ^g   Untch, Michael ^h   Perez, Edith A ⁱ   Piccart Gebhart, Martine J ^j   Viale, Giuseppe ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f MAYO CLINIC   (United States)

^g Klinikum Offenbach   (Germany)

^h HELIOS KLINIKUM BERLIN BUCH   (Germany)

ⁱ MAYO CLINIC   (United States)

^j JULES BORDET INSTITUTE   (Belgium)

more..

Author keywords

Breast cancer; Central laboratory review; Estrogen receptor testing; HER2 testing; Local versus central laboratory concordance

Indexed keywords

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; ITALY; QUINAZOLINES; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84894073975     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2827-0     Document Type: Article

References (10)

1. Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373
2. Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852
3. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
4. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48-e72
5. Dako product insert for Dako ER/PR pharmDX kit for the Dako Autostainer, edition 10/11
6. Phillips T, Murray G, Wakamiya K et al (2007) Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol (AIMM) 15:325-331
7. Dowsett M, Hanna WM, Kockx M et al (2007) Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 20:584-591
8. Perez EA, Press MF, Dueck AC et al (2013) Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 138:99-108
9. Wolff AC, Hammond EH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update. J Clin Oncol 31:3997-4013
10. Perez EA, Dueck AC, McCullough AE et al (2012) Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104:159-162